Log in to search using one of your social media accounts:

 

Scientists Have Made Their First Attempt at Gene Editing Inside a Human Patient
(OAKLAND, Calif.) — Scientists for the first time have tried editing a gene inside the body in a bold attempt to permanently change a person’s DNA to try to cure a disease. The experiment was done Monday in California on 44-year-old Brian Madeux. Through an IV, he received billions of copies of a corrective gene and a genetic tool to cut his DNA in a precise spot. “It’s kind of humbling” to be the first to test this, said Madeux, who has a metabolic disease called Hunter syndrome. “I’m willing to take that risk. Hopefully it will help me and other people.” Signs of whether i...
Source: TIME.com: Top Science and Health Stories - November 15, 2017 Category: Consumer Health News Authors: Marilynn Marchione / AP Tags: Uncategorized gene editing Genetics health Innovation onetime overnight Research Source Type: news

Elimination organs hit the hardest by air pollution: Toxic particles cause cancer in the kidneys, bladder, bowel and lungs
(Natural News) Air pollution causes a myriad of illnesses, most notably diseases concerning the heart and lungs. Now a groundbreaking study has revealed that the toxins we are inhaling daily may also cause kidney and bladder cancer. According to Dr. Michelle Turner, first author of the study: “This research suggests that air pollution was not... (Source: NaturalNews.com)
Source: NaturalNews.com - November 13, 2017 Category: Consumer Health News Source Type: news

Genes that hold the clues to bladder cancer and its treatment
(University of Leeds) Scientists have discovered the 'genetic signatures' of the most common form of bladder cancer -- and it could open up the possibility of better-targeted treatment, according to research published today. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2017 Category: Cancer & Oncology Source Type: news

Cancer treatment response may be affected by gut bacteria
Conclusion This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. We don't know what the conditions that required antibiotic treatment were and whether these could have affected the response to immunotherapy. We don't know whether the antibiotics themselves influenced how well the immunotherapy worked, or whether it was their effect on gut bacteria. We also don't know whether having high levels of part...
Source: NHS News Feed - November 3, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

UK's NICE Gives Roche Drug Green Light for Bladder Cancer UK's NICE Gives Roche Drug Green Light for Bladder Cancer
Britain's healthcare cost-effectiveness agency NICE, which decides if medicines should be used on the state health service, has decided Roche's immunotherapy drug Tecentriq is worth using to treat certain patients with bladder cancer.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 2, 2017 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Air pollution linked to kidney, bladder and bowel cancer
Pollution has been linked to lung cancer but little was known about other types. Now a Barcelona Institute of Global Health study shows it raises the risk of dying from kidney or bladder cancer by 15%. (Source: the Mail online | Health)
Source: the Mail online | Health - November 1, 2017 Category: Consumer Health News Source Type: news

Digging For Gold
This article appeared in the most recent edition of our specialist publication,Trends in Medical Affairs.Click here to download a copy.   Related Content: Pragmatic Trials: The Real-World Data RevolutionNavigating The New LandscapeWhen Real-World Evidence met Patient-CentricityBig Data, Huge OpportunityPrimary Event: Medical Affairs Europe 2018Pr écis: As Medical gets more involved in real-world evidence, what challenges does it face in proving the value of a medicine?Premium`: Freemium`: Channels: CommercialTags: medical affairsChannelimage:  (Source: EyeForPharma)
Source: EyeForPharma - November 1, 2017 Category: Pharmaceuticals Authors: Lucy Fulford Source Type: news

UK's NICE gives Roche drug green light for bladder cancer
LONDON (Reuters) - Britain's healthcare cost-effectiveness agency NICE, which decides if medicines should be used on the state health service, has decided Roche's immunotherapy drug Tecentriq is worth using to treat certain patients with bladder cancer. (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Air pollution is associated with cancer mortality beyond lung cancer
(Barcelona Institute for Global Health (ISGlobal)) A large scale epidemiological study associates some air pollutants with kidney, bladder and colorectal cancer death. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 31, 2017 Category: Biology Source Type: news

Medical News Today: Bladder cancer: Noninvasive urine test steps closer
At the SIU symposium, researchers revealed how a novel noninvasive urine test can accurately detect bladder cancer in low- and high-risk patients. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 27, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Bladder Cancer in Children
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 26, 2017 Category: General Medicine Source Type: news

Arsenic Reductions in Drinking Water Tied to Fewer Cancer Deaths
Researchers estimate that a new government rule resulted in 200 to 900 fewer lung and bladder cancers and 50 fewer skin cancers annually. (Source: NYT Health)
Source: NYT Health - October 24, 2017 Category: Consumer Health News Authors: NICHOLAS BAKALAR Tags: Water Skin Arsenic Water Pollution Bladder Lungs Deaths (Fatalities) Cancer Source Type: news

Study indicates arsenic can cause cancer decades after exposure ends
(Oxford University Press USA) A new paper published in the Journal of the National Cancer Institute shows that arsenic in drinking water may have one of the longest dormancy periods of any carcinogen. By tracking the mortality rates of people exposed to arsenic-contaminated drinking water in a region in Chile, the researchers provide evidence of increases in lung, bladder, and kidney cancer even 40 years after high arsenic exposures ended. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 24, 2017 Category: International Medicine & Public Health Source Type: news

Tighter Rules on Arsenic in Water Saved Lives: Study
EPA moves likely cut cases of lung and bladder cancer (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - October 24, 2017 Category: Cancer & Oncology Source Type: news

Tighter Rules on Arsenic in Water Saved Lives: Study
EPA moves likely cut cases of lung and bladder cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 23, 2017 Category: Cancer & Oncology Tags: Family Medicine, Oncology, Preventive Medicine, News, Source Type: news

Tighter Rules on Arsenic in Water Saved Lives
EPA moves likely cut cases of lung and bladder cancer Source: HealthDay Related MedlinePlus Pages: Arsenic, Drinking Water (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 23, 2017 Category: Consumer Health News Source Type: news

Tighter Rules on Arsenic in Water Saved Lives: Study
MONDAY, Oct. 23, 2017 -- U.S. government limits on arsenic in drinking water has likely averted hundreds of cases of lung and bladder cancer annually, a new study suggests. After the Environmental Protection Agency introduced tighter limits on... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 23, 2017 Category: General Medicine Source Type: news

Arsenic exposure in us public drinking water declines following new EPA regulations
(Columbia University's Mailman School of Public Health) Exposure to arsenic in drinking water was significantly reduced among Americans using public water systems following the Environmental Protection Agency regulation on maximum levels of arsenic. Compliance led to a decline of 17 percent in levels of urinary arsenic, equivalent to an estimated reduction of over 200 cases of lung and bladder disease every year. However, there were no improvements in arsenic exposure rates among users of private wells, which are not federally regulated. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 22, 2017 Category: Cancer & Oncology Source Type: news

Prostate problem? Take 2 nuts
By age 60, you have a 50/50 chance of having a clinically enlarged prostate. And it only gets worse every year. When your prostate isn’t functioning properly, it’s hard to enjoy life. Traditional doctors give you two choices. Go under the knife or you take Big Pharma’s drugs. Either way, you have a good chance of ending up with your manhood on the line… If you have surgery, there’s a big risk you’ll be saying goodbye to your sex life for good. The rate of impotence is a shocking 50 to 60% after prostate surgery.1 Big Pharma’s meds to shrink your prostate are no better. These sy...
Source: Al Sears, MD Natural Remedies - October 19, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news

Liquid Biopsy Promising for Monitoring Post-cystectomy Bladder Cancer Liquid Biopsy Promising for Monitoring Post-cystectomy Bladder Cancer
Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 17, 2017 Category: Pathology Tags: Pathology & Lab Medicine News Source Type: news

Are All Tumors in the Bladder Cancerous?
Title: Are All Tumors in the Bladder Cancerous?Category: Doctor's& Expert's views on SymptomsCreated: 10/12/2017 12:00:00 AMLast Editorial Review: 10/12/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 12, 2017 Category: Cancer & Oncology Source Type: news

Johns Hopkins scientists develop experimental 'nano-chemo' particle to treat bladder cancer
(Johns Hopkins Medicine) Working with mice and rats, Johns Hopkins researchers have developed a way to successfully deliver nano-sized, platinum-based chemotherapy drugs to treat a form of bladder cancer called nonmuscle-invasive that is found in the lining of the organ and has not invaded deeper into bladder tissue. The tiny drug-infused particles, they say, potentially offer a less toxic clinical alternative to standard chemotherapy delivered intravenously or through a catheter inserted into the bladder. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 12, 2017 Category: Cancer & Oncology Source Type: news

KC biotech developing KU cancer drug clears big FDA hurdle
A Kansas City biotech company moved one large step closer to FDA approval for its cancer drug. CicloMed LLC gained Food and Drug Administration approval to begin human clinical trials for bladder cancer patients, the company announced Wednesday. About 79,000 new cases of bladder cancer will be diagnosed this year, according to the American Cancer Society. The treatment not only is an advan cement for bladder cancer patients, but it also is the first drug developed at The University of Kansas Cancer… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 11, 2017 Category: Pharmaceuticals Authors: Elise Reuter Source Type: news

KC biotech developing KU cancer drug clears big FDA hurdle
A Kansas City biotech company moved one large step closer to FDA approval for its cancer drug. CicloMed LLC gained Food and Drug Administration approval to begin human clinical trials for bladder cancer patients, the company announced Wednesday. About 79,000 new cases of bladder cancer will be diagnosed this year, according to the American Cancer Society. The treatment not only is an advan cement for bladder cancer patients, but it also is the first drug developed at The University of Kansas Cancer… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 11, 2017 Category: Biotechnology Authors: Elise Reuter Source Type: news

New Tool IDs Mortality Risk After Bladder Cancer Surgery
Tool incorporates the relative contribution of tumor stage, lymph node involvement (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 11, 2017 Category: Cancer & Oncology Tags: Internal Medicine, Nursing, Oncology, Pathology, Radiology, Surgery, Urology, Journal, Source Type: news

Baltimore biotech firm bringing new cancer diagnosis test to market
BCD Innovations Inc.'s first product will be a new kind of diagnostic test for bladder cancer, the most recurrent kind of cancer. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 10, 2017 Category: Biotechnology Authors: Morgan Eichensehr Source Type: news

Roche bladder cancer drug struggles as medics focus on survival
LONDON (Reuters) - Roche's immunotherapy drug Tecentriq has lost market share to Merck& Co's rival Keytruda since a clinical trial showed the Swiss company's medicine failed to improve overall survival in bladder cancer. (Source: Reuters: Health)
Source: Reuters: Health - October 5, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Haematuria more common in people taking antithrombotics
Use of antithrombotics linked to risk of haematuria-related complications in older people Related items fromOnMedica Risk of bladder cancer with non-visible haematuria quantified for the first time Self-managing anticoagulants may cut risks after surgery Extending anticoagulation duration cuts risk of VTE recurrence Rising use of antithrombotics linked to subdural haematoma (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 4, 2017 Category: UK Health Source Type: news

High-precision radiotherapy for prostate cancer 'shows promise'
Conclusion This study shows some promising results for targeted pelvic lymph node radiotherapy for men with advanced localised prostate cancer. However, these results can only be treated as preliminary findings for now. This was an early-stage trial that aimed to investigate whether the treatment approach is safe and to get an idea of what doses may be suitable for assessment in further trials. Although it can give an indication of effectiveness, this was not the main aim of the study. Men were not randomised to a treatment group, which means there may have been some differences in the cancers or patient characteristics of...
Source: NHS News Feed - September 26, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Coffee supports the gall bladder and reduces liver cancer, as revealed in new meta-analysis
(Natural News) A cup of coffee a day supports two very important detoxification organs, the liver and gall bladder. The properties of organic coffee bean communicate a cleansing effect to the human body. Organic coffee is revered as a therapeutic agent in Gerson Therapy cancer treatment clinics and is used via enema to quickly stimulate... (Source: NaturalNews.com)
Source: NaturalNews.com - September 25, 2017 Category: Consumer Health News Source Type: news

Roche cancer immunotherapy Tecentriq wins EU approval
ZURICH (Reuters) - Roche immunotherapy Tecentriq has won European Union approval for treating advanced lung and bladder cancer, the Swiss drugmaker said. (Source: Reuters: Health)
Source: Reuters: Health - September 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Roche receives EU approval of TECENTRIQ ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Roche today announced that the European Commission (EC) has granted a marketing authorisation for TECENTRIQ (atezolizumab) as a monotherapy for the treatment of people with locally advanced or metastatic non-small cell lung cancer (NSCLC) after they have been previously treated with chemotherapy regardless of PD-L1 status. (Source: Roche Media News)
Source: Roche Media News - September 22, 2017 Category: Pharmaceuticals Source Type: news

Roche receives EU approval of TECENTRIQ ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Roche today announced that the European Commission (EC) has granted a marketing authorisation for TECENTRIQ (atezolizumab) as a monotherapy for the treatment of people with locally advanced or metastatic non-small cell lung cancer (NSCLC) after they have been previously treated with chemotherapy regardless of PD-L1 status. (Source: Roche Investor Update)
Source: Roche Investor Update - September 22, 2017 Category: Pharmaceuticals Source Type: news

New Link Seen Between Gene Fusion and Bladder Cancer
Previously overlooked section of fusion found to negatively impact cancer cells, researchers say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 18, 2017 Category: Cancer & Oncology Tags: Oncology, Pathology, Urology, Journal, Source Type: news

Mature results favor pembrolizumab as second-line treatment for bladder cancer
(European Society for Medical Oncology) Mature results from the KEYNOTE-045 trial to be presented today at the ESMO 2017 Congress in Madrid have confirmed significantly longer survival in patients with advanced urothelial cancer who receive the checkpoint inhibitor pembrolizumab after initial chemotherapy, compared to an alternative chemotherapy regimen. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 10, 2017 Category: Cancer & Oncology Source Type: news

Urine test UroMark could save NHS millions
Developed by researchers at University College London, UroMark can detect bladder cancer in 98 per cent of cases, a figure equivalent to the results of cystoscopies. (Source: the Mail online | Health)
Source: the Mail online | Health - September 9, 2017 Category: Consumer Health News Source Type: news

Adding modified herpes virus to immunotherapy shows promise for treating advanced melanoma
FINDINGSIn a two-year study at UCLA, nearly two-thirds of people with advanced melanoma responded positively to a treatment that combines the immunotherapy drug pembrolizumab with a herpes virus called talimogene laherpareovec, or T-VEC. Researchers led by Dr. Antoni Ribas found that the treatment ’s side effects were manageable, and comparable to side effects for people who took either pembrolizumab or T-VEC as a standalone treatment.BACKGROUNDUCLA scientists are testing the combination of pembrolizumab (marketed as Keytruda) and T-VEC (marketed as Imlygic) as a treatment option for people with advanced melanoma tha...
Source: UCLA Newsroom: Health Sciences - September 7, 2017 Category: Universities & Medical Training Source Type: news

Sharks with frickin' lasers: Gold nanoparticles fry cancer on glowing mice
(University of Colorado Anschutz Medical Campus) A University of Colorado Cancer Center study takes a new approach to killing cancer: Why not fry it into oblivion with vibrating gold nanoparticles? Results are published online ahead of print in the journal Bladder Cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 30, 2017 Category: International Medicine & Public Health Source Type: news

Study highlights new link between gene fusion and bladder and brain cancer
(University of Warwick) A study by the University of Warwick sheds new light on gene fusion in bladder and brain cancer.Researchers have found that a previously overlooked part of a specific gene fusion has a worsening effect on cancer cells. They have also found that preventing cell 'signalling' from this particular fusion may not be an effective route for future cancer treatment research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 29, 2017 Category: Cancer & Oncology Source Type: news

Bristol-Myers, Daiichi Sankyo to test Opdivo combo for cancers
(Reuters) - Bristol-Myers Squibb Co and Daiichi Sankyo said they were evaluating a combination of Bristol-Myers' immuno-oncology drug, Opdivo, with the Japanese company's experimental drug in patients with breast and bladder cancers. (Source: Reuters: Health)
Source: Reuters: Health - August 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

New hope for victims of 'Cinderella' bladder cancer
Atezolizumab, can help those with an advanced form of the disease survive an average of almost 16 months compared to a survival rate of only 7.9 months for patients on chemotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - August 19, 2017 Category: Consumer Health News Source Type: news

Nanotech, immunotherapy combo vaccinates mouse against cancer
Researchers from Duke University combined an FDA-approved cancer immunotherapy with gold nanostars to boost the cancer-killing abilities of both therapies, according to a study published this week in Scientific Reports. The combination therapy cured two mice and vaccinated one against bladder cancer, the team reported. Get the full story at our sister site, Drug Delivery Business News. The post Nanotech, immunotherapy combo vaccinates mouse against cancer appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 18, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Oncology Pharmaceuticals Research & Development Duke University Source Type: news

Another Study Ties Pioglitazone to Bladder Cancer Risk (CME/CE)
(MedPage Today) -- Risk emerged within first 2 years; attenuated after discontinuing (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - August 10, 2017 Category: Pediatrics Source Type: news

Bladder Preservation Yields Poorer Survival in Urothelial Carcinoma
In patients with stage II to III urothelial carcinoma, bladder-preservation therapy was associated with poorer overall survival compared with radical cystectomy, according to a database study. (Source: CancerNetwork)
Source: CancerNetwork - August 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers News Source Type: news

UK Finds Roche Bladder Cancer Drug Too Costly for Routine Use UK Finds Roche Bladder Cancer Drug Too Costly for Routine Use
Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq (atezolizumab) is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances.Reuters Health Information (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - August 4, 2017 Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news

Urothelial Cancer Response to Neoadjuvant Chemo Varies by Histologic Variant
Certain histologic variants of urothelial bladder cancer benefit more from neoadjuvant chemotherapy, according to a new study. (Source: CancerNetwork)
Source: CancerNetwork - August 3, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers News Source Type: news

Breakthrough in tackling aggressive cancers
Finding could lead to new treatments Related items fromOnMedica Nasopharyngeal carcinoma and sinus cancer Underused cancer test could improve treatment of colon cancer Blood test may pick up bladder cancer ’s return before symptoms appear Tall men at higher risk of aggressive prostate cancer UK spends 20% less on cancer treatment than rest of EU (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 3, 2017 Category: UK Health Source Type: news

UK finds Roche bladder cancer drug too costly for routine use
LONDON (Reuters) - Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances. (Source: Reuters: Health)
Source: Reuters: Health - August 2, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer
[6-15-2011] The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 1, 2017 Category: Drugs & Pharmacology Source Type: news

Immediate Chemotherapy After TURBT Reduces NMIBC Recurrence Risk
An immediate instillation of chemotherapy with mitomycin C following transurethral resection of a bladder tumor reduced the risk of recurrence of non –muscle-invasive bladder cancer (NMIBC). (Source: CancerNetwork)
Source: CancerNetwork - July 24, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers News Source Type: news